SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 58.17+3.9%Dec 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Archie Meeties who wrote (14508)12/4/2004 11:49:46 PM
From: NeuroInvestment  Read Replies (1) of 52153
 
<<f acp-104 lite follows another metabolic pathway, then this side effect may be avoided>>

Yes. But that's a big IF. Usually companies will at least quietly telegraph their belief that a new molecule might avoid the sins of the old. When I visited them in August, I asked them about ACP-104 and agranulocytosis. If they think 104 sidesteps that oxidative pathway, they weren't saying so at the time. Their Phase IIa program probably won't be big enough to be definitive one way or the other.

Harry
NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News